SCHEMBL25050720

SCHEMBL25050720

CC(=O)NCCCC#N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11757886 0.91 KDM4E (0.67)
SCHEMBL28810976 0.91 KDM4E (0.67)
SCHEMBL48475 0.86
SCHEMBL1681786 0.79 KDM4E (0.35)
SCHEMBL293573 0.79
SCHEMBL21680768 0.79
SCHEMBL1519900 0.79
SCHEMBL19176934 0.78 MEN1 (0.64)
SCHEMBL20220922 0.77
SCHEMBL9058741 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023016529-A1 NAPHTHYRIDINE DERIVATIVE AS ATR INHIBITOR AND METHOD FOR PREPARING SAME 微境生物医药科技(上海)有限公司 2023-02-16 WO disclosed
CN-1065744-C Treatment of diseases associated with platelet derived growth factor such as cancer SUGEN INC (US) 2001-05-16 CN disclosed
CN-1128496-A Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor SUGEN INC (US) 1996-08-07 CN disclosed